:::System.Xml.XmlException: This is an unexpected token. The expected token is 'QUOTE'. Line 9, position 136. at System.Xml.XmlScanner.ScanToken(Int32 expected) at System.Xml.XmlTextReader.SetLiteralValues(XmlAttributeTokenInfo fld) at System.Xml.XmlTextReader.SetAttributeValues() at System.Xml.XmlTextReader.ParseElement() at System.Xml.XmlTextReader.Read() at System.Xml.XmlValidatingReader.ReadNoCollectTextToken() at System.Xml.XmlValidatingReader.Read() at System.Xml.XmlLoader.LoadCurrentNode() at System.Xml.XmlLoader.LoadDocSequence(XmlDocument parentDoc) at System.Xml.XmlLoader.Load(XmlDocument doc, XmlReader reader, Boolean preserveWhitespace) at System.Xml.XmlDocument.Load(XmlReader reader) at System.Xml.XmlDocument.Load(String filename) at Websites.xmlList.CreateChildControls() The Biomolecular and High Throughput Screening Information Portal - eposter - default
Technology Networks

Latest Posters

A Comparison of AlphaLISA Bead-Based Luminescence and Electrochemiluminescence Immunoassay Technologies for Detection of Human EPO, Amyloid Beta 42 and VEGF in Complex Sample Matrices
Anuradha Prasad, Ashleigh Price, Stephen Hurt, Rathnam Chaguturu,
PerkinElmer/The University of Kansas
The University of Kansas in collaboration with PerkinElmer Inc. worked on looking at the comparison of the AlphaLISA Technology and an Electrochemiluminescence Technology to measure assay windows, lower and upper detection limits and intra - and inter-assay precision. In this study, three AlphaLISA no-wash assays, which employ a faster and less complex protocol, were found to deliver highly sensitive and accurate results, equivalent to those obtained in ECL technology.

Real-Time Monitoring of ATP Depletion Suitable for HTS
Arne Lundin,
BioThema AB
ATP depletion assays of kinases, ATPases and aminoacyl tRNA synthetases can be performed in the presence of firefly luciferase/luciferin, by monitoring the light emission continuously. Such assays are preferably set up to result in a first order reaction rate with respect to ATP consumption.

Microcarrier based production of cryopreserved cells
Sharon Davies, Lynne Smith, Sian Kalinka, Philip Meyler, Chris Jones, Rahman Ismail, Elizabeth Price, Stephen Game, J M Kendall., GE Healthcare, GE Healthcare
The use of cellular assays in drug screening continues to grow with over 50% of primary screens using cell based formats in 2006. The majority of cells used in the drug discovery industry are fresh, using ‘just in time’ batch processing from in house facilities. This process could give rise to a number of issues, namely batch variation, scheduling of cell production and capacity management. We describe the use of microcarrier technology in combination with a suitably configured bioreactor to pro

Smart Solutions in drug discovery
Ian Kalinka, Lynne Smith, Elizabeth Price, Angela Marenghi, J.M.Kendall, Ray Ismai, GE Healthcare
Here we present data on the development of a large scale production process for the provision of two different cryopreserved transiently transfected cell lines. Included is identification of a suitable transfection reagent that is efficient, non-toxic and cost effective. This process has been validated using these two cell lines and two different cell-based assays.

The application of microcarrier technology for the provision of receptor membranes for high-throughput screening
Liz Price, Angela Marenghi, Gareth Ellis#, Stephen Game, Rahman Ismail, GE Healthcare, GE Healthcare
The recent growth in cell use for drug discovery, particularly for high-throughput screening (HTS), has posed a number of challenges including batch performance, cell production scheduling and capacity management in response to the increasing demands for cells and assay components derived from cells (e.g. membrane fractions).

Quality Tools and their Application in the Production of Cellular Reagents for Screening Assays.
Sharon Davies, Lynne Smith, Lisa Bailey, Martyn Birch, Rahman Ismail, Peter Tatnell, Michelle Doyle, Liz Price and J.M Kendall, GE Healthcare, GE Healthcare
The use of mammalian cell based assays in compound screening continues to grow. Over 50% of all screening assays (HTS and HCA) now utilise cells or cell derived reagents.